Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -701.04% is 128% below its 5-year average of -307.41%, around the middle of its 5-year range (-4571.84%–1191.86%).
117.89% below its 12-month average of -321.74%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 1191.86%.
EBITDA MARGIN
-701.04%
EBITDA MARGIN AVG TTM
-321.74%
EBITDA MARGIN AVG 3Y
-291.62%
EBITDA MARGIN AVG 5Y
-307.41%
EBITDA MARGIN AVG 10Y
-160.62%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-117.89%
CURRENT VS 3Y AVG
-140.39%
CURRENT VS 5Y AVG
-128.05%
CURRENT VS 10Y AVG
-336.45%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kyntra Bio, Inc.
Market Cap
$23.96M
EBITDA Margin
-701.04%
TTM Avg
-321.74%
3Y Avg
-291.62%
5Y Avg
-307.41%
Market Cap
$24.74M
EBITDA Margin
-710238.40%
TTM Avg
-369696.29%
3Y Avg
-185511.92%
5Y Avg
-193923.76%
Market Cap
$24.96M
EBITDA Margin
-883.91%
TTM Avg
-2536.80%
3Y Avg
-2479.09%
5Y Avg
-2025.77%
Market Cap
$22.65M
EBITDA Margin
-7.62%
TTM Avg
-5.66%
3Y Avg
-2.78%
5Y Avg
-31.67%
Market Cap
$25.43M
EBITDA Margin
-989.17%
TTM Avg
-572.43%
3Y Avg
-292.90%
5Y Avg
-228.52%
Market Cap
$26.58M
EBITDA Margin
-541.66%
TTM Avg
-507.83%
3Y Avg
-427.73%
5Y Avg
-407.72%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyntra Bio, Inc. (KYNB) | $23.96M | -701.04% | -321.74% | -291.62% | -307.41% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.74M | -710238.40% | -369696.29% | -185511.92% | -193923.76% |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.96M | -883.91% | -2536.80% | -2479.09% | -2025.77% |
| Rein Therapeutics Inc. (RNTX)vs › | $22.87M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.65M | -7.62% | -5.66% | -2.78% | -31.67% |
| LeonaBio, Inc. (LONA)vs › | $22.28M | N/A | N/A | N/A | N/A |
| iTonic Holdings Ltd. (ITOC)vs › | $25.43M | -989.17% | -572.43% | -292.90% | -228.52% |
| Modular Medical, Inc. (MODD)vs › | $21.60M | N/A | N/A | N/A | N/A |
| InspireMD, Inc. (NSPR)vs › | $26.58M | -541.66% | -507.83% | -427.73% | -407.72% |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.92M | -13586.02% | -13586.02% | -13586.02% | -13586.02% |
Gross Margin
91.4%
EBITDA Margin
-701.0%
Operating Margin
-712.7%
Net Margin
3967.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 1191.86% |
| 2026-03-31 | -369.48% |
| 2025-12-31 | -1101.33% |
| 2025-09-30 | -481.23% |
| 2025-06-30 | -848.52% |
| 2025-03-31 | -528.19% |
| 2024-12-31 | 74.08% |
| 2024-09-30 | -34.62% |
| 2024-06-30 | -4571.84% |
| 2024-03-31 | -190.67% |
| 2023-12-31 | -192.79% |
| 2023-09-30 | -152.25% |
| 2023-06-30 | -192.55% |
| 2023-03-31 | -202.22% |
| 2022-12-31 | -184.66% |
| 2022-09-30 | -578.19% |
| 2022-06-30 | -253.55% |
| 2022-03-31 | -99.31% |
| 2021-12-31 | -801.90% |
| 2021-09-30 | 34.34% |
| 2021-06-30 | -531.68% |
| 2021-03-31 | -169.37% |
| 2020-12-31 | -80.78% |
| 2020-09-30 | 86.08% |
| 2020-06-30 | -185.63% |
| 2020-03-31 | -309.87% |
| 2019-12-31 | -1196.60% |
| 2019-09-30 | -141.92% |
| 2019-06-30 | 61.69% |
| 2019-03-31 | -182.42% |
| 2018-12-31 | 20.16% |
| 2018-09-30 | -141.81% |
| 2018-06-30 | -49.32% |
| 2018-03-31 | -122.41% |
| 2017-12-31 | -52.45% |
| 2017-09-30 | -126.53% |
| 2017-06-30 | -102.98% |
| 2017-03-31 | -110.99% |
| 2016-12-31 | -93.26% |
| 2016-09-30 | -68.40% |
| 2016-06-30 | 31.38% |
| 2016-03-31 | -89.40% |
| 2015-12-31 | -192.23% |
| 2015-09-30 | -216.75% |
| 2015-06-30 | 50.37% |
| 2015-03-31 | -265.89% |
| 2014-12-31 | -290.80% |
| 2014-09-30 | -260.64% |
| 2014-06-30 | 55.70% |
| 2014-03-31 | -74.37% |
| 2013-12-31 | -192.07% |
| 2013-09-30 | 59.61% |
| 2013-06-30 | -39.32% |
| 2013-03-31 | -541.66% |
